International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 1 , Pages 23-27 , 1 May 2008

Improved Outcomes With Higher Doses for Salvage Radiotherapy After Prostatectomy

  • Christopher R. King, Ph.D., M.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Christopher R. King, Ph.D., M.D., Department of Radiation Oncology, Stanford University School of Medicine, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305. Tel: (650) 736-0698; Fax: (650) 725-8231
    • ,
  • Michael T. Spiotto, M.D., Ph.D.

Received 18 June 2007 ,Revised 30 August 2007 ,Accepted 12 September 2007.

References 

  1. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: A randomized controlled trial (EORTC trial 22911). Lancet. 2005;366:572–578
  2. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized trial. JAMA. 2006;296:2329–2335
  3. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325–1332
  4. Hayes SB, Pollack A. Parameters for treatment decisions for salvage radiation therapy. J Clin Oncol. 2005;23:8204–8211
  5. Cox JD, Gallagher MJ, Hammond EH, et al. ASTRO Consensus Panel. Consensus statement on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising PSA levels after radical prostatectomy. J Clin Oncol. 1999;17:1155–1163
  6. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  7. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 2005;294:1233–1239
  8. Kupelian P, Kuban D, Thames H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005;61:415–419
  9. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising PSA after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys. 2000;48:369–375
  10. Valicenti RK, Gomella LG, Ismail M, et al. Effect of higher radiation dose on biochemical control after radical prostatectomy for pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys. 1998;42:501–506
  11. MacDonald KO, Schild SE, Vora SA, et al. Radiotherapy for men with isolated increase in serum PSA after radical prostatectomy. J Urol. 2003;170:1833–1837
  12. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;3:457–500
  13. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97:1248–1253
  14. Feng M, Hanlon AL, Pisansky TM, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1417–1423
  15. Schiffner DC, Gottschalk AR, Lometti M, et al. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;67:610–619

 Conflict of interest: none.

PII: S0360-3016(07)04378-7

doi: 10.1016/j.ijrobp.2007.09.047

International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 1 , Pages 23-27 , 1 May 2008

Article Tools

* Image Usage & Resolution